強生(JNJ.US)雙抗一線組合療法3期結果積極可改善癌症患者總生存期

智通財經

01-08

智通財經APP獲悉，強生公司(JNJ.US)今日宣佈其3期MARIPOSA研究的頂線結果。分析顯示，與當前標準治療相比，其雙特異性抗體Rybrevant(amivantamab)聯合第三代表皮生長因子受體(EGFR)酪氨酸激酶抑制劑(TKI)口服藥物Lazcluze(lazertinib)，作爲一線療法治療帶有EGFR外顯子19缺失(ex19del)或外顯子21中L858R替代突變的局部晚期或轉移性非小細胞肺癌(NSCLC)成年患者時，可在臨牀與統計學上顯著改善患者的總生存期(OS)。

MARIPOSA是一項隨機3期研究，共招募1074名患者。評估Rybrevant與Lazcluze聯用，與活性對照奧希替尼(osimertinib)相比的療效和安全性。研究的主要終點爲根據RECIST v1.1標準、經獨立盲法中央評審(BICR)評估的無進展生存期(PFS)。次要終點包括OS、客觀緩解率(ORR)、緩解持續時間(DOR)、第二次無進展生存期(PFS2)以及顱內PFS。之前試驗結果顯示，與活性對照藥物相比，Rybrevant與Lazcluze聯合療法可降低患者疾病進展或死亡風險達30%。美國FDA在去年8月根據該試驗的PFS結果，批准此聯合療法用於治療相應的患者羣體。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2501184037"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501184037\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501184037?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-01-08 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501184037","market":"sh","top_or_hot":-1,"title":"強生(JNJ.US)雙抗一線組合療法3期結果積極 可改善癌症患者總生存期","media":"智通財經","content":"<html><body><p>智通財經APP獲悉，<a href=\"https://laohu8.com/S/JNJ\">強生</a>公司(JNJ.US)今日宣佈其3期MARIPOSA研究的頂線結果。分析顯示，與當前標準治療相比，其雙特異性抗體Rybrevant(amivantamab)聯合第三代表皮生長因子受體(EGFR)酪氨酸激酶抑制劑(TKI)口服藥物Lazcluze(lazertinib)，作爲一線療法治療帶有EGFR外顯子19缺失(ex19del)或外顯子21中L858R替代突變的局部晚期或轉移性非小細胞肺癌(NSCLC)成年患者時，<strong>可在臨牀與統計學上顯著改善患者的總生存期(OS)</strong>。</p><p>MARIPOSA是一項隨機3期研究，共招募1074名患者。評估Rybrevant與Lazcluze聯用，與活性對照奧希替尼(osimertinib)相比的療效和安全性。研究的主要終點爲根據RECIST v1.1標準、經獨立盲法中央評審(BICR)評估的無進展生存期(PFS)。次要終點包括OS、客觀緩解率(ORR)、緩解持續時間(DOR)、第二次無進展生存期(PFS2)以及顱內PFS。<strong>之前試驗結果顯示，與活性對照藥物相比，Rybrevant與Lazcluze聯合療法可降低患者疾病進展或死亡風險達30%。</strong>美國FDA在去年8月根據該試驗的PFS結果，批准此聯合療法用於治療相應的患者羣體。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>強生(JNJ.US)雙抗一線組合療法3期結果積極 可改善癌症患者總生存期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n強生(JNJ.US)雙抗一線組合療法3期結果積極 可改善癌症患者總生存期\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-01-08 14:30</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP獲悉，<a href=\"https://laohu8.com/S/JNJ\">強生</a>公司(JNJ.US)今日宣佈其3期MARIPOSA研究的頂線結果。分析顯示，與當前標準治療相比，其雙特異性抗體Rybrevant(amivantamab)聯合第三代表皮生長因子受體(EGFR)酪氨酸激酶抑制劑(TKI)口服藥物Lazcluze(lazertinib)，作爲一線療法治療帶有EGFR外顯子19缺失(ex19del)或外顯子21中L858R替代突變的局部晚期或轉移性非小細胞肺癌(NSCLC)成年患者時，<strong>可在臨牀與統計學上顯著改善患者的總生存期(OS)</strong>。</p><p>MARIPOSA是一項隨機3期研究，共招募1074名患者。評估Rybrevant與Lazcluze聯用，與活性對照奧希替尼(osimertinib)相比的療效和安全性。研究的主要終點爲根據RECIST v1.1標準、經獨立盲法中央評審(BICR)評估的無進展生存期(PFS)。次要終點包括OS、客觀緩解率(ORR)、緩解持續時間(DOR)、第二次無進展生存期(PFS2)以及顱內PFS。<strong>之前試驗結果顯示，與活性對照藥物相比，Rybrevant與Lazcluze聯合療法可降低患者疾病進展或死亡風險達30%。</strong>美國FDA在去年8月根據該試驗的PFS結果，批准此聯合療法用於治療相應的患者羣體。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1234783.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BSNM7G36.USD","symbol_name":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1234783.html","article_id":"2501184037","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501184037","pubTimestamp":1736317855,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP獲悉，強生公司今日宣佈其3期MARIPOSA研究的頂線結果。MARIPOSA是一項隨機3期研究，共招募1074名患者。之前試驗結果顯示，與活性對照藥物相比，Rybrevant與Lazcluze聯合療法可降低患者疾病進展或死亡風險達30%。美國FDA在去年8月根據該試驗的PFS結果，批准此聯合療法用於治療相應的患者羣體。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4592":"伊斯兰概念","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4559":"巴菲特持仓","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4568":"美国抗疫概念","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4581":"高盛持仓","BK4504":"桥水持仓","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","JNJ":"强生","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4532":"文艺复兴科技持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"Johnson & Johnson (JNJ.US) double-antibody first-line combination therapy phase 3 results can improve the overall survival of cancer patients","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"智通財經APP獲悉，強生公司(JNJ.US)今日宣佈其3期MARIPOSA研究的頂線結果。分析顯示，與當前標準治療相比，其雙特異性抗體Rybrevant(amivantamab)聯合第三代表皮生長因子受體(EGFR)酪氨酸激酶抑制劑(TKI)口服藥物Lazcluze(lazertinib)，作為一線療法治療帶有EGFR外顯子19缺失(ex19del)或外顯子21中L858R替代突變的局部晚期或轉移性非小細胞肺癌(NSCLC)成年患者時，可在臨牀與統計學上顯著改善患者的總生存期(OS)。MARIPOSA是一項隨機3期研究，共招募1074名患者。評估Rybrevant與Lazcluze聯用，與活性對照奧希替尼(osimertinib)相比的療效和安全性。研究的主要終點為根據RECIST v1.1標準、經獨立盲法中央評審(BICR)評估的無進展生存期(PFS)。次要終點包括OS、客觀緩解率(ORR)、緩解持續時間(DOR)、第二次無進展生存期(PFS2)以及顱內PFS。之前試驗結果顯示，與活性對照藥物相比，Rybrevant與Lazcluze聯合療法可降低患者疾病進展或死亡風險達30%。美國FDA在去年8月根據該試驗的PFS結果，批准此聯合療法用於治療相應的患者羣體。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}